Long-term effectiveness and safety of omalizumab in pediatric and adult patients with moderate-to-severe inadequately controlled allergic asthma
Omalizumab is recommended as an add-on therapy in patients aged ≥6 years with inadequately controlled, moderate-to-severe persistent allergic asthma. The efficacy and safety of omalizumab treatment in allergic asthma clinical trials and its effectiveness in the real world have been reported in numer...
Guardat en:
| Autors principals: | , , , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Elsevier
2022-10-01
|
| Col·lecció: | World Allergy Organization Journal |
| Matèries: | |
| Accés en línia: | http://www.sciencedirect.com/science/article/pii/S1939455122000710 |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|